trans-N-hydroxy-3-p-tolyl-acrylamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: trans-N-hydroxy-3-p-tolyl-acrylamide
• 英文别名: (E)-N-hydroxy-3-(p-tolyl)acrylamide；trans-4-methylcinnamohydroxamic acid；(2E)-N-hydroxy-3-(4-methylphenyl)prop-2-enamide；(E)-N-hydroxy-3-(4-methylphenyl)prop-2-enamide
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: DEQAPAAUGTUJDH-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-methylcinnamic acid 在 2-chlorotrityl hydroxylamine resin 、 6-氯-1-羟基苯并三氮唑 、 N,N'-二异丙基碳二亚胺 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 、 二氯甲烷 为溶剂， 反应 24.5h， 以92.5%的产率得到trans-N-hydroxy-3-p-tolyl-acrylamide
  参考文献：
  名称：

  Identification of a Potent Botulinum Neurotoxin A Protease Inhibitor Using in Situ Lead Identification Chemistry

  摘要：

  Botulinum neurotoxins (BoNTs), etiological agents of the deadly food poisoning disease botulism, are the most toxic proteins currently known. By using in situ lead identification chemistry, we have uncovered the first class of inhibitors that displays nanomolar potency. From a 15 mu M lead compound, structure-activity relationship studies were performed granting the most potent BoNT/A inhibitor reported to date that displays an inhibition constant of 300 nM.

  DOI：

  10.1021/ol0603211

文献信息

• [EN] METHODS OF REDUCING VIRULENCE IN BACTERIA<br/>[FR] PROCÉDÉS DE RÉDUCTION DE LA VIRULENCE DE BACTÉRIES
  申请人：UWM RES FOUNDATION INC

  公开号：WO2011103189A1

  公开（公告）日：2011-08-25

  A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.

  一种减少细菌毒力的方法，包括至少一个GacS/GacA型系统、一个HrpX/HrpY型系统、一个T3SS型系统和一个Rsm型系统，该方法包括将细菌与本文描述的化合物的有效量接触。
• METHODS OF REDUCING VIRULENCE IN BACTERIA
  申请人：Yang Ching-Hong

  公开号：US20120322769A1

  公开（公告）日：2012-12-20

  A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.

  一种减少细菌毒力的方法，包括至少一种GacS/GacA型系统、HrpX/HrpY型系统、T3SS型系统和Rsm型系统中的一种，该方法包括将细菌与本文所述化合物的有效量接触。
• Inhibitors of histone deacetylase
  申请人：Methylgene, Inc.

  公开号：EP1748046A2

  公开（公告）日：2007-01-31

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• Inhibitors of histone deacetylase and prodrugs thereof
  申请人：MethylGene Inc.

  公开号：EP2573069A2

  公开（公告）日：2013-03-27

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物、其原药和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• TREATMENT OF SOLID TUMORS
  申请人：President and Fellows of Harvard College

  公开号：EP3354265A1

  公开（公告）日：2018-08-01

  The invention relates to methods of treating protein degradation disorders, such as cellular proliferative disorders (e.g., cancer). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating solid tumors. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.

  本发明涉及治疗蛋白质降解紊乱的方法，如细胞增殖紊乱（如癌症）。本发明提供了使用侵袭酶体抑制剂或侵袭酶体抑制剂和蛋白酶体抑制剂组合治疗这些疾病的方法和药物组合物。本发明还涉及治疗实体瘤的方法和药物组合物。本发明还提供了新的HDAC/TDAC抑制剂和侵袭体抑制剂以及制备这些化合物的合成方法。